Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.

Frontiers in oncology

Pfeiffer MM, Burow H, Schleicher S, Handgretinger R, Lang P.
PMID: 23641363
Front Oncol. 2013 Apr 29;3:99. doi: 10.3389/fonc.2013.00099. eCollection 2013.

Epigenetic drugs like histone deacetylase inhibitors (HDACi) and DNA-methyltransferase inhibitors (DNMTi) have been shown to be effective against a variety of tumor entities. Among different molecular anticancer activities of epigenetic active substances, up-regulation of natural killer (NK) cell ligands...

Cite
Pfeiffer MM, Burow H, Schleicher S, et al. Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Front Oncol. 2013;3:99doi: 10.3389/fonc.2013.00099.
Pfeiffer, M. M., Burow, H., Schleicher, S., Handgretinger, R., & Lang, P. (2013). Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Frontiers in oncology, 399. https://doi.org/10.3389/fonc.2013.00099
Pfeiffer, Matthias Manuel, et al. "Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia." Frontiers in oncology vol. 3 (2013): 99. doi: https://doi.org/10.3389/fonc.2013.00099
Pfeiffer MM, Burow H, Schleicher S, Handgretinger R, Lang P. Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Front Oncol. 2013 Apr 29;3:99. doi: 10.3389/fonc.2013.00099. eCollection 2013. PMID: 23641363; PMCID: PMC3638146.
Copy Download .nbib Format: NLM
Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study.

Stem cells international

Hartleif S, Schumm M, Döring M, Mezger M, Lang P, Dahlke MH, Riethmüller J, Königsrainer A, Handgretinger R, Nadalin S, Sturm E.
PMID: 28740511
Stem Cells Int. 2017;2017:2352954. doi: 10.1155/2017/2352954. Epub 2017 Jun 27.

BACKGROUND: Calcineurin inhibitors (CNI) have significantly improved patient and graft survival in pediatric liver transplantation (pLT). However, CNI toxicity leads to significant morbidity. Moreover, CNIs cannot prevent long-term allograft injury. Mesenchymal stem (stromal) cells (MSC) have potent immunomodulatory properties,...

Cite
Hartleif S, Schumm M, Döring M, et al. Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study. Stem Cells Int. 2017;2017:2352954doi: 10.1155/2017/2352954.
Hartleif, S., Schumm, M., Döring, M., Mezger, M., Lang, P., Dahlke, M. H., Riethmüller, J., Königsrainer, A., Handgretinger, R., Nadalin, S., & Sturm, E. (2017). Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study. Stem cells international, 20172352954. https://doi.org/10.1155/2017/2352954
Hartleif, Steffen, et al. "Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study." Stem cells international vol. 2017 (2017): 2352954. doi: https://doi.org/10.1155/2017/2352954
Hartleif S, Schumm M, Döring M, Mezger M, Lang P, Dahlke MH, Riethmüller J, Königsrainer A, Handgretinger R, Nadalin S, Sturm E. Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study. Stem Cells Int. 2017;2017:2352954. doi: 10.1155/2017/2352954. Epub 2017 Jun 27. PMID: 28740511; PMCID: PMC5504958.
Copy Download .nbib Format: NLM
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.

OncoTargets and therapy

Queudeville M, Handgretinger R, Ebinger M.
PMID: 28790849
Onco Targets Ther. 2017 Jul 19;10:3567-3578. doi: 10.2147/OTT.S103470. eCollection 2017.

Patients with refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL) have a dismal prognosis of around 5% long-term survival when treated with cytotoxic chemotherapy and allogenic stem cell transplantation. T-cell immunobased strategies open up new therapeutic perspectives. Blinatumomab is...

Cite
Queudeville M, Handgretinger R, Ebinger M. Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. Onco Targets Ther. 2017;10:3567-3578doi: 10.2147/OTT.S103470.
Queudeville, M., Handgretinger, R., & Ebinger, M. (2017). Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. OncoTargets and therapy, 103567-3578. https://doi.org/10.2147/OTT.S103470
Queudeville, Manon, et al. "Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab." OncoTargets and therapy vol. 10 (2017): 3567-3578. doi: https://doi.org/10.2147/OTT.S103470
Queudeville M, Handgretinger R, Ebinger M. Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. Onco Targets Ther. 2017 Jul 19;10:3567-3578. doi: 10.2147/OTT.S103470. eCollection 2017. PMID: 28790849; PMCID: PMC5530848.
Copy Download .nbib Format: NLM
Serving his patients with passion and dedication-Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer.

Bone marrow transplantation

Bader P, Handgretinger R, Klingebiel T.
PMID: 32094416
Bone Marrow Transplant. 2020 Jun;55(6):1209-1210. doi: 10.1038/s41409-020-0840-6. Epub 2020 Feb 24.

No abstract available.

Cite
Bader P, Handgretinger R, Klingebiel T. Serving his patients with passion and dedication-Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer. Bone Marrow Transplant. 2020;55(6):1209-1210doi: 10.1038/s41409-020-0840-6.
Bader, P., Handgretinger, R., & Klingebiel, T. (2020). Serving his patients with passion and dedication-Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer. Bone marrow transplantation, 55(6), 1209-1210. https://doi.org/10.1038/s41409-020-0840-6
Bader, Peter, et al. "Serving his patients with passion and dedication-Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer." Bone marrow transplantation vol. 55,6 (2020): 1209-1210. doi: https://doi.org/10.1038/s41409-020-0840-6
Bader P, Handgretinger R, Klingebiel T. Serving his patients with passion and dedication-Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer. Bone Marrow Transplant. 2020 Jun;55(6):1209-1210. doi: 10.1038/s41409-020-0840-6. Epub 2020 Feb 24. PMID: 32094416.
Copy Download .nbib Format: NLM
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer.

Nature communications

Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L.
PMID: 34853305
Nat Commun. 2021 Dec 01;12(1):7005. doi: 10.1038/s41467-021-27303-7.

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we show that blood platelets...

Cite
Hinterleitner C, Strähle J, Malenke E, et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12(1):7005doi: 10.1038/s41467-021-27303-7.
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., Salih, H., Borst, O., Kopp, H. G., & Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature communications, 12(1), 7005. https://doi.org/10.1038/s41467-021-27303-7
Hinterleitner, Clemens, et al. "Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer." Nature communications vol. 12,1 (2021): 7005. doi: https://doi.org/10.1038/s41467-021-27303-7
Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021 Dec 01;12(1):7005. doi: 10.1038/s41467-021-27303-7. PMID: 34853305.
Copy Download .nbib Format: NLM
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.

Biomolecules

Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D, Schleicher S, Handgretinger R, Huber SM, Ganser K.
PMID: 34827559
Biomolecules. 2021 Oct 21;11(11). doi: 10.3390/biom11111561.

Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed...

Cite
Zirjacks L, Stransky N, Klumpp L, et al. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules. 2021;11(11)doi: 10.3390/biom11111561.
Zirjacks, L., Stransky, N., Klumpp, L., Prause, L., Eckert, F., Zips, D., Schleicher, S., Handgretinger, R., Huber, S. M., & Ganser, K. (2021). Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules, 11(11), . https://doi.org/10.3390/biom11111561
Zirjacks, Lisa, et al. "Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study." Biomolecules vol. 11,11 (2021). doi: https://doi.org/10.3390/biom11111561
Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D, Schleicher S, Handgretinger R, Huber SM, Ganser K. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules. 2021 Oct 21;11(11). doi: 10.3390/biom11111561. PMID: 34827559; PMCID: PMC8615869.
Copy Download .nbib Format: NLM
Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.

Blood advances

Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, Bourquin JP, Handgretinger R, Brethon B, Rössig C, Kormany WN, Viswagnachar P, Chen-Santel C.
PMID: 34979020
Blood Adv. 2022 Jan 03; doi: 10.1182/bloodadvances.2021005579. Epub 2022 Jan 03.

The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T-cell engager molecule, for treatment of pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days,

Cite
Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022;doi: 10.1182/bloodadvances.2021005579.
Locatelli, F., Zugmaier, G., Mergen, N., Bader, P., Jeha, S., Schlegel, P. G., Bourquin, J. P., Handgretinger, R., Brethon, B., Rössig, C., Kormany, W. N., Viswagnachar, P., & Chen-Santel, C. (2022). Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood advances, . https://doi.org/10.1182/bloodadvances.2021005579
Locatelli, Franco, et al. "Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis." Blood advances vol. (2022). doi: https://doi.org/10.1182/bloodadvances.2021005579
Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, Bourquin JP, Handgretinger R, Brethon B, Rössig C, Kormany WN, Viswagnachar P, Chen-Santel C. Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022 Jan 03; doi: 10.1182/bloodadvances.2021005579. Epub 2022 Jan 03. PMID: 34979020.
Copy Download .nbib Format: NLM
Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.

Stem cells and development

Döring M, Cabanillas Stanchi KM, Lenglinger K, Treuner C, Gieseke F, Erbacher A, Mezger M, Vaegler M, Schlegel PG, Greil J, Bettoni da Cunha Riehm C, Faul C, Schumm M, Lang P, Handgretinger R, Müller I.
PMID: 33446053
Stem Cells Dev. 2021 Mar;30(5):234-246. doi: 10.1089/scd.2020.0191. Epub 2021 Feb 19.

Steroid-refractory graft-versus-host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). Alternative treatment options are often insufficient. Several studies have proven the efficacy of mesenchymal stromal cells (MSCs) in the treatment of therapy-refractory acute GvHD...

Cite
Döring M, Cabanillas Stanchi KM, Lenglinger K, et al. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem Cells Dev. 2021;30(5):234-246doi: 10.1089/scd.2020.0191.
Döring, M., Cabanillas Stanchi, K. M., Lenglinger, K., Treuner, C., Gieseke, F., Erbacher, A., Mezger, M., Vaegler, M., Schlegel, P. G., Greil, J., Bettoni da Cunha Riehm, C., Faul, C., Schumm, M., Lang, P., Handgretinger, R., & Müller, I. (2021). Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem cells and development, 30(5), 234-246. https://doi.org/10.1089/scd.2020.0191
Döring, Michaela, et al. "Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease." Stem cells and development vol. 30,5 (2021): 234-246. doi: https://doi.org/10.1089/scd.2020.0191
Döring M, Cabanillas Stanchi KM, Lenglinger K, Treuner C, Gieseke F, Erbacher A, Mezger M, Vaegler M, Schlegel PG, Greil J, Bettoni da Cunha Riehm C, Faul C, Schumm M, Lang P, Handgretinger R, Müller I. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem Cells Dev. 2021 Mar;30(5):234-246. doi: 10.1089/scd.2020.0191. Epub 2021 Feb 19. PMID: 33446053.
Copy Download .nbib Format: NLM
RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of .

Bio-protocol

Haque AA, Weinmann P, Biswas S, Handgretinger R, Mezger M, Kormann MSD, Antony JS.
PMID: 33855105
Bio Protoc. 2020 Dec 20;10(24):e3850. doi: 10.21769/BioProtoc.3850. eCollection 2020 Dec 20.

The mRNA therapeutics is a new class of medicine to treat many various diseases. However,

Cite
Haque AA, Weinmann P, Biswas S, et al. RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of . Bio Protoc. 2020;10(24):e3850doi: 10.21769/BioProtoc.3850.
Haque, A. A., Weinmann, P., Biswas, S., Handgretinger, R., Mezger, M., Kormann, M. S. D., & Antony, J. S. (2020). RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of . Bio-protocol, 10(24), e3850. https://doi.org/10.21769/BioProtoc.3850
Haque, Akm Ashiqul, et al. "RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of ." Bio-protocol vol. 10,24 (2020): e3850. doi: https://doi.org/10.21769/BioProtoc.3850
Haque AA, Weinmann P, Biswas S, Handgretinger R, Mezger M, Kormann MSD, Antony JS. RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of . Bio Protoc. 2020 Dec 20;10(24):e3850. doi: 10.21769/BioProtoc.3850. eCollection 2020 Dec 20. PMID: 33855105; PMCID: PMC8032499.
Copy Download .nbib Format: NLM
Correction to: Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature.

BMC pediatrics

Schober S, Schilbach K, Doering M, Cabanillas Stanchi KM, Holzer U, Kasteleiner P, Schittenhelm J, Schaefer JF, Mueller I, Lang P, Handgretinger R.
PMID: 31791281
BMC Pediatr. 2019 Dec 02;19(1):470. doi: 10.1186/s12887-019-1851-6.

After publication of the original article (1), it was brought to our attention that references 24 and 31 are inappropriately cited in the article.

Cite
Schober S, Schilbach K, Doering M, et al. Correction to: Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature. BMC Pediatr. 2019;19(1):470doi: 10.1186/s12887-019-1851-6.
Schober, S., Schilbach, K., Doering, M., Cabanillas Stanchi, K. M., Holzer, U., Kasteleiner, P., Schittenhelm, J., Schaefer, J. F., Mueller, I., Lang, P., & Handgretinger, R. (2019). Correction to: Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature. BMC pediatrics, 19(1), 470. https://doi.org/10.1186/s12887-019-1851-6
Schober, Sarah, et al. "Correction to: Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature." BMC pediatrics vol. 19,1 (2019): 470. doi: https://doi.org/10.1186/s12887-019-1851-6
Schober S, Schilbach K, Doering M, Cabanillas Stanchi KM, Holzer U, Kasteleiner P, Schittenhelm J, Schaefer JF, Mueller I, Lang P, Handgretinger R. Correction to: Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature. BMC Pediatr. 2019 Dec 02;19(1):470. doi: 10.1186/s12887-019-1851-6. PMID: 31791281; PMCID: PMC6886177.
Copy Download .nbib Format: NLM
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer.

Nature communications

Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L.
PMID: 34853305
Nat Commun. 2021 Dec 01;12(1):7005. doi: 10.1038/s41467-021-27303-7.

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we show that blood platelets...

Cite
Hinterleitner C, Strähle J, Malenke E, et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12(1):7005doi: 10.1038/s41467-021-27303-7.
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., Salih, H., Borst, O., Kopp, H. G., & Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature communications, 12(1), 7005. https://doi.org/10.1038/s41467-021-27303-7
Hinterleitner, Clemens, et al. "Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer." Nature communications vol. 12,1 (2021): 7005. doi: https://doi.org/10.1038/s41467-021-27303-7
Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021 Dec 01;12(1):7005. doi: 10.1038/s41467-021-27303-7. PMID: 34853305; PMCID: PMC8636618.
Copy Download .nbib Format: NLM
Arginase 1.

Experimental dermatology

Neri D, Carevic-Neri M, Brück J, Holstein J, Schäfer I, Solimani F, Handgretinger R, Hartl D, Ghoreschi K.
PMID: 33528891
Exp Dermatol. 2021 Jun;30(6):782-791. doi: 10.1111/exd.14298. Epub 2021 Feb 23.

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which are characterized by their capability to suppress T-cell responses. While MDSCs have been traditionally associated with cancer diseases, their role as regulators of autoimmune diseases is...

Cite
Neri D, Carevic-Neri M, Brück J, et al. Arginase 1. Exp Dermatol. 2021;30(6):782-791doi: 10.1111/exd.14298.
Neri, D., Carevic-Neri, M., Brück, J., Holstein, J., Schäfer, I., Solimani, F., Handgretinger, R., Hartl, D., & Ghoreschi, K. (2021). Arginase 1. Experimental dermatology, 30(6), 782-791. https://doi.org/10.1111/exd.14298
Neri, Davide, et al. "Arginase 1." Experimental dermatology vol. 30,6 (2021): 782-791. doi: https://doi.org/10.1111/exd.14298
Neri D, Carevic-Neri M, Brück J, Holstein J, Schäfer I, Solimani F, Handgretinger R, Hartl D, Ghoreschi K. Arginase 1. Exp Dermatol. 2021 Jun;30(6):782-791. doi: 10.1111/exd.14298. Epub 2021 Feb 23. PMID: 33528891.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries